MabVax Therapeutics Announces Acceptance of Three Poster Presentations at the 2018 American Association for Cancer Research (AACR) Annual Meeting

- Company to present interim results from the Phase 1 clinical trial of MVT-1075, a radioimmunotherapy product for the treatment of patients with relapsed / refractory pancreatic cancer

- Company to present results from preclinical work on a fully human antibody that binds to Tn and sTn antigens that are expressed on ovarian and breast cancers

- Company to present results from preclinical work with MVT-2163, an immunoPET imaging agent, evaluating potential as a companion diagnostic for patients with pancreatic and CA19-9 positive cancers

SAN DIEGO, March 15, 2018 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company, announced today that it will present three posters at the American Association for Cancer Research (AACR) Annual Meeting being held April 14-18, 2018 in Chicago, Illinois at McCormick Place. The first poster session features MVT-1075 ($^{177}$Lu-CHX-A*-DTPA-HuMab5B1), the Company's novel fully human antibody-based radioimmunotherapy (RIT) currently being evaluated in clinical development for the treatment of pancreatic cancer and other CA19-9 positive malignancies. The second presentation will feature preclinical investigations on the novel fully human antibody targeting the Thomsen-nouveau (Tn) and the sialyl Tn (sTn) cancer antigens which are highly overexpressed on ovarian and breast cancer tissues. The third poster features the Company's immunoPET imaging agent MVT-2163 ($^{89}$Zr-DFO-HuMab5B1), as a companion diagnostic for use in pancreatic cancer and CA19-9 positive malignancies.
Paul Maffuid, Ph.D., Executive Vice President of Research and Development of MabVax, stated, "We look forward to sharing the significant progress we have made through these clinical and preclinical studies that continue to establish our growing body of data supporting the development of MVT-1075 for the treatment of pancreatic cancer and other CA19-9 cancers, and our most advanced research program focused on the Tn and sTn cancer antigens."

Dr. Maffuid continued, "MVT-1075 potentially represents a more potent analog of our fully human HuMab-5B1 therapeutic antibody and establishing these safety and early response data bring us an important step closer in providing a much-needed treatment option for patients who have these devastating cancers. Equally important, our anti-Tn/sTn antibody program has made significant progress over the last few months and these data are the subject of partnering interest."

MabVax Abstracts and Poster Presentations

**Sunday April 15, 2018 from 1:00 PM – 5:00 PM CDT:**
Title: *A fully human antibody binds Tn and sTn carbohydrate antigens specifically on serine residues, without need for polypeptide interaction*
Session Location: Poster Section 43
Abstract Number: LB-002, Poster Board Number 2
Presenting Author: Jonah Rainey, Ph.D., Executive Director, Antibody Research MabVax Therapeutics

**Tuesday April 17, 2018 from 8:00 AM – 12:00 PM CDT:**
Title: *Phase I dose escalation study of 177Lu-HuMab-5B1 (MVT-1075) in combination with MVT-5873 as radioimmunotherapy (RIT) in subjects with relapsed / refractory pancreatic cancer or other CA19-9+ malignancies*
Session Location: McCormick Place South, Hall A, Poster Section 42
Abstract Number: CT140, Poster Board Number 23
Presenting Author: Paul Maffuid, Ph.D., Executive Vice President, Research & Development MabVax Therapeutics

**Tuesday April 17, 2018 from 8:00 AM – 12:00 PM CDT:**
Title: *PEGylated Hyaluronidase Increases Tumor Uptake of^{89}Zr-DFO-HuMab-5B1 (MVT-2163) in a CA19-9 Positive Hyaluronan-Accumulating Pancreatic Cancer Model*
About MVT-1075

MVT-1075 is a radioimmunotherapy product that combines established efficacy of radiation therapy with tumor specific targeting. It has the potential to deliver a more potent HuMab-5B1 based product. MVT-1075 uses small doses of the Company's MVT-5873 antibody, coupled to a radioisotope to target pancreatic cancer cells and kill them.

About the HuMab-Tn Antibody Targeting Tn and sTn

HuMab-Tn is a fully human antibody derived from a patient vaccinated with a pool of cancer glycans, including Tn. The antibody has been affinity-matured and demonstrates highly selective Tn/sTn glycan binding. Further, the antibody recognizes a wide array of cancers, particularly ovarian and breast including approximately 90% of triple negative breast cancers tested.

About MVT-2163

MVT-1075 is an immunoPET imaging agent product that combines the established PET imaging capabilities of $^{89}$Zr with 5B1 tumor specific targeting. It has the potential to aid in identifying the best surgical treatment options for patients with pancreatic cancer and as a potential companion diagnostic with treatment options.

About MabVax:

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer. Our antibody MVT-5873, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9, and is currently in Phase 1 clinical trials as a therapeutic agent for patients with pancreatic cancer and other CA19-9 positive tumors. CA19-9 is expressed in over 90% of pancreatic cancers and in other diseases including small cell lung and GI cancers. CA19-9 plays an important role in tumor adhesion and metastasis, and is a marker of an aggressive cancer phenotype. CA19-9 serum levels are considered a valuable adjunct in the diagnosis, prognosis and treatment monitoring of pancreatic cancer. With our collaborators including Memorial Sloan Kettering Cancer Center, Sarah Cannon Research Institute, Honor Health and Imaging Endpoints, we have treated 50 patients with either our therapeutic antibody designated as MVT-5873 or our PET imaging diagnostic product designated as MVT-2163 in Phase 1 clinical studies, and demonstrated early safety and specificity for the target. Patient dosing is underway for our lead development program in Phase 1 clinical study of the Company's radioimmunotherapy product MVT-1075. Our human antibody targeting Tn and sTn is in preclinical development. For additional information, please visit the Company’s website, www.mabvax.com.
Forward Looking Statements:

This press release on announcing acceptance of three posters at the April 2018 American Association for Cancer Research (AACR) Annual Meeting contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to the Company’s MVT-1075 clinical development program, the Company's human antibody targeting Tn and sTn in preclinical development, and the Company's immunoPET imaging agent MVT-2163. We have no assurance that all the product development pipeline will be fully developed by the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2016, as amended and supplemented from time to time and the Company's Quarterly Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.

Investor Contact:

Jenene Thomas
Jenene Thomas Communications, LLC
Phone: 908-938-1475
Email: MBVX@jtcir.com

Media Contact:

Travis Kruse, Ph.D.
Russo Partners LLC
Phone: 212-845-4272
Email: travis.kruse@russopartnersllc.com


SOURCE MabVax Therapeutics Holdings, Inc.